title: Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
abstract: We have studied several aspects of DNA damage formation and repair in human ovarian cancer cell lines which have become resistant to cisplatin through continued exposure to the anticancer drug. The resistant cell lines A2780/cp70 and 2008/c13*5.25 were compared with their respective parental cell lines, A2780 and 2008. Cells in culture were treated with cisplatin, and the two main DNA lesions formed, intrastrand adducts and interstrand cross-links, were quantitated before and after repair incubation. This quantitation was done for total genomic lesions and at the level of individual genes. In the overall genome, the initial frequency of both cisplatin lesions assayed was higher in the parental than in the derivative resistant cell lines. Nonetheless, the total genomic repair of each of these lesions was not increased in the resistant cells. These differences in initial lesion frequency between parental and resistant cell lines were not observed at the gene level. Resistant and parental cells had similar initial frequencies of intrastrand adducts and interstrand cross-links in the dihydrofolate reductase (DHFR) gene and in several other genes after cisplatin treatment of the cells. There was no increase in the repair efficiency of intrastrand adducts in the DHFR gene in resistant cell lines compared with the parental partners. However, a marked and consistent repair difference between parental and resistant cells was observed for the gene-specific repair of cisplatin interstrand cross-links. DNA interstrand cross-links were removed from three genes, the DHFR, multidrug resistance (MDR1), and delta-globin genes, much more efficiently in the resistant cell lines than in the parental cell lines. Our findings suggest that acquired cellular resistance to cisplatin may be associated with increased gene-specific DNA repair efficiency of a specific lesion, the interstrand cross-link.
authors.affiliation: Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland 20892.
authors.forename: W
authors.initials: W
authors.lastname: Zhen
authors.forename: C J
authors.initials: CJ
authors.lastname: Link
authors.forename: P M
authors.initials: PM
authors.lastname: O'Connor
authors.forename: E
authors.initials: E
authors.lastname: Reed
authors.forename: R
authors.initials: R
authors.lastname: Parker
authors.forename: S B
authors.initials: SB
authors.lastname: Howell
authors.forename: V A
authors.initials: VA
authors.lastname: Bohr
mesh_terms: D015139:Blotting, Southern; D002945:Cisplatin / Q000494:pharmacology*; D003432:Cross-Linking Reagents / Q000494:pharmacology*; D004249:DNA Damage; D004260:DNA Repair; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D015894:Genome, Human; D006801:Humans; D010051:Ovarian Neoplasms; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics; D014407:Tumor Cells, Cultured; D005719:gamma-Globulins / Q000235:genetics
chemical_list: D003432:Cross-Linking Reagents; D005719:gamma-Globulins; D013762:Tetrahydrofolate Dehydrogenase; D002945:Cisplatin